Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
4.310
+0.030 (0.70%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Xeris Biopharma Holdings Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Cash & Equivalents | 71.62 | 67.45 | 121.97 | 67.27 | 37.6 | Upgrade
|
| Short-Term Investments | - | 5 | - | 35.16 | 96.19 | Upgrade
|
| Cash & Short-Term Investments | 71.62 | 72.45 | 121.97 | 102.43 | 133.79 | Upgrade
|
| Cash Growth | -1.15% | -40.60% | 19.07% | -23.44% | 77.09% | Upgrade
|
| Accounts Receivable | 40.42 | 39.2 | 30.83 | 17.46 | 6.88 | Upgrade
|
| Receivables | 40.42 | 39.2 | 30.83 | 17.46 | 6.88 | Upgrade
|
| Inventory | 48.18 | 38.84 | 24.74 | 18.12 | 8.35 | Upgrade
|
| Prepaid Expenses | 7.45 | 5.78 | 9.29 | 4.59 | 3.2 | Upgrade
|
| Total Current Assets | 167.66 | 156.26 | 186.82 | 142.6 | 152.21 | Upgrade
|
| Property, Plant & Equipment | 28.21 | 29.18 | 9.51 | 6.63 | 6.71 | Upgrade
|
| Goodwill | 22.86 | 22.86 | 22.86 | 22.86 | - | Upgrade
|
| Other Intangible Assets | 98.92 | 109.76 | 120.61 | 131.45 | - | Upgrade
|
| Other Long-Term Assets | 5.41 | 4.54 | 4.73 | 0.83 | 0.23 | Upgrade
|
| Total Assets | 323.06 | 322.6 | 344.52 | 304.36 | 159.15 | Upgrade
|
| Accounts Payable | 2.29 | 11.57 | 4.61 | 8.92 | 3.12 | Upgrade
|
| Accrued Expenses | 56.8 | 45.66 | 44.09 | 51.17 | 21.07 | Upgrade
|
| Current Portion of Long-Term Debt | 15.1 | - | - | - | - | Upgrade
|
| Current Portion of Leases | 6.08 | 3.5 | 1.58 | - | - | Upgrade
|
| Other Current Liabilities | 20.17 | 34.47 | 23.35 | 18.95 | 4.02 | Upgrade
|
| Total Current Liabilities | 100.44 | 95.19 | 73.62 | 79.04 | 28.21 | Upgrade
|
| Long-Term Debt | 217.01 | 190.93 | 187.08 | 88.07 | 87.02 | Upgrade
|
| Long-Term Leases | 33.26 | 34.76 | 9.4 | - | - | Upgrade
|
| Long-Term Deferred Tax Liabilities | - | 2.27 | 3.52 | 4.94 | - | Upgrade
|
| Other Long-Term Liabilities | 1.97 | 6.23 | 25.72 | 37.08 | 10.16 | Upgrade
|
| Total Liabilities | 352.68 | 329.38 | 299.34 | 209.13 | 125.39 | Upgrade
|
| Common Stock | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Additional Paid-In Capital | 642.26 | 610.25 | 599.97 | 555.36 | 371.13 | Upgrade
|
| Retained Earnings | -671.86 | -617.03 | -554.77 | -460.11 | -337.39 | Upgrade
|
| Comprehensive Income & Other | -0.03 | -0.03 | -0.02 | -0.03 | 0.01 | Upgrade
|
| Total Common Equity | -29.62 | -6.78 | 45.19 | 95.23 | 33.76 | Upgrade
|
| Shareholders' Equity | -29.62 | -6.78 | 45.19 | 95.23 | 33.76 | Upgrade
|
| Total Liabilities & Equity | 323.06 | 322.6 | 344.52 | 304.36 | 159.15 | Upgrade
|
| Total Debt | 271.45 | 229.19 | 198.06 | 88.07 | 87.02 | Upgrade
|
| Net Cash (Debt) | -199.83 | -156.74 | -76.09 | 14.37 | 46.77 | Upgrade
|
| Net Cash Growth | - | - | - | -69.28% | 171.21% | Upgrade
|
| Net Cash Per Share | -1.36 | -1.14 | -0.56 | 0.18 | 1.10 | Upgrade
|
| Filing Date Shares Outstanding | 153.94 | 140.45 | 137.29 | 135.52 | 59.76 | Upgrade
|
| Total Common Shares Outstanding | 149.43 | 138.13 | 136.27 | 124.87 | 59.61 | Upgrade
|
| Working Capital | 67.22 | 61.07 | 113.2 | 63.56 | 124.01 | Upgrade
|
| Book Value Per Share | -0.20 | -0.05 | 0.33 | 0.76 | 0.57 | Upgrade
|
| Tangible Book Value | -151.4 | -139.41 | -98.28 | -59.08 | 33.76 | Upgrade
|
| Tangible Book Value Per Share | -1.01 | -1.01 | -0.72 | -0.47 | 0.57 | Upgrade
|
| Machinery | 6.26 | 5.65 | 5.68 | 5.43 | 4.32 | Upgrade
|
| Leasehold Improvements | 6.06 | 5.98 | 5.07 | 5.03 | 4.63 | Upgrade
|
Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.